¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"independent binding"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • corticosteroid-binding globulin
    ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇձ۷κҸ°
  • cortisol-binding globulin
    ÄÚÆ¼¼Ö°áÇձ۷κҸ°
  • gonadal steroid-binding globulin
    »ý½Ä»ù½ºÅ×·ÎÀ̵å°áÇձ۷κҸ°
  • iron binding protein
    ö°áÇմܹéÁú
  • iron-binding capacity
    ö°áÇÕ´É
  • ligand binding site
    ¸®°£µå°áÇÕºÎÀ§
  • olfactory binding protein
    Èİ¢°áÇմܹéÁú
  • orthodontic binding wire
    ±³Á¤¿ë¹­±âö»ç, ±³Á¤¿ë°áÂû¼±
  • protein binding
    ´Ü¹éÁú°áÇÕ
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • sex hormone-binding globulin
    ¼ºÈ£¸£¸ó°áÇձ۷κҸ°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • protein binding
    ´Ü¹é°áÇÕ
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • cross-binding
    ±³Â÷¿¬°á
  • competitive protein binding radioassay
    °æÇմܹé°áÇÕ¹æ»çÃøÁ¤(¹ý)
  • corticosteroid-binding globulin
    ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇձ۷κҸ°
  • cortisol-binding globulin
    ÄÚ¸£Æ¼¼Ö°áÇÕ±Û·Îºí¸°
  • iron-binding capacity
    ö°áÇÕ´É
  • gonadal steroid-binding globulin
    »ý½Ä»ù½ºÅ×·ÎÀ̵å°áÇձ۷κҸ°
  • sex hormone-binding globulin
    ¼ºÈ£¸£¸ó°áÇÕ±Û·Îºí¸°
  • testosterone-binding globulin
    Å×½ºÅ佺Å׷аáÇձ۷κҸ°
  • thyroxine-binding globulin
    Ƽ·Ï½Å°áÇÕ±Û·Îºí¸°
  • iron binding protein
    ö°áÇմܹéÁú
  • olfactory binding protein
    Èİ¢°áÇմܹé
  • orthodontic binding wire
    ±³Á¤¿ë¹­±âö»ç, ±³Á¤¿ë°áÂû¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • TBPA => thyroxine binding prealbumin
    ŸÀ̷ϽŰáÇÕÀü¾ËºÎ¹Î
  • TIBC => total iron binding capacity
    ÃÑö°áÇÕ´É
  • UIBC => unsaturated iron binding capacity
    ºÒÆ÷ȭö°áÇÕ´É
  • actin-binding protein
    ¾×ƾ °áÇմܹé(¡­Ì¿ùêÓ±ÛÜ)
  • androgen- binding protein
    ¸¸¼ºÈ£¸£¸ó °áÇմܹé
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • human zona binding assay
    »ç¶÷Á¤ÀÚ Åõ¸í´ëºÎÂø°Ë»ç
  • plasma protein binding
    Ç÷Àå´Ü¹é°áÇÕ.
  • protein,actin-binding
    ¾×ƾ-°áÇÕ(´Ü¹é)
  • receptor binding
    ¼ö¿ëü°áÇÕ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody, complement binding
    º¸Ã¼°áÇÕÇ×ü
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • binding
    °áÇÕ(Ì¿ùê)
  • binding
    ¹­À½, °áÇÕ.
  • binding activity
    °áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding activity
    ¸é¿ª°áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding affinity
    °áÇÕģȭ¼º(Ì¿ùêöÑûúàõ)
  • binding displacement analysis
    °áÇÕº¯À§ºÐ¼®(Ì¿ùêܨêÈÝÂà°).
  • binding energy
    °áÇÕ¿¡³ÊÁö
  • binding energy
    °áÇÕ(Ì¿ùê)¿¡³ÊÁö
  • binding orbit
    °áÇձ˵µ(Ì¿ùêÏùÔ³).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • binding site
    °áÇÕ(Ì¿ùê)ÀÚ¸®
  • cellular retinol-binding protein
    ¼¼Æ÷(á¬øà) ·¹Æ¼³î°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
  • competitive protein-binding technique
    °æÇÕÀû ´Ü¹éÁú °áÇÕ¼ú(ÌæùêîÜÓ±ÛÜòõÌ¿ùêâú)
  • complement binding reaction
    º¸Ã¼°íÁ¤ ¹ÝÀÀ(ÜÍô÷ͳïÒÚãëë)
  • cooperative binding
    Çùµ¿ °áÇÕ(úðÔÒÌ¿ùê)
  • corticosteroid-binding globulin
    "ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇÕ(Ì¿ùê) ±Û·ÎºÒ¸°, (ÔÒ) transcortin"
  • corticosteroid-binding protein
    "ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ), (ÔÒ) transcortin"
  • cortisol-binding globulin
    "ÄÚÆ¼¼Ö°áÇÕ(Ì¿ùê) ±Û·ÎºÒ¸°, (ÔÒ) transcortin"
  • cortisol-binding protein
    ÄÚÆ¼¼Ö°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ) (ÔÒ) transcortin
  • DNA binding protein
    DNA °áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ) (ÔÒ) single strand binding protein
  • excluded site binding
    ¹èÁ¦(ÛÉð¶)ÀÚ¸® °áÇÕ(Ì¿ùê)
  • fraction-antibody binding
    ºÎºÐÇ×ü °áÇÕ(Ý»ÝÂù÷ô÷Ì¿ùê)
  • GTP-binding protein
    GTP°áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • guanine-nucleotide-binding protein
    ±¸¾Æ´Ñ´©Å¬·¹¿ÀŸÀÌµå °áÇÕ ´Ü¹éÁú(Ì¿ùêÓ±ÛÜòõ)
  • iron-binding globulin
    ö°áÇÕ(ôÑÌ¿ùê) ±Û·Îºí¸°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BIPLED bilateral, independent, periodic, lateralized epileptiform discharge
BSIF bile salt independent fraction
HI half-scan with interpolation; head injury; health insurance; hearing impaired; heart infusion; hemag...
IID insulin-independent diabetes
IIDM insulin-independent diabetes mellitus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NIS Newly Independent States
SIMCA Soft independent modelling of class analogy
TI T cell independent
TI T independent
TI Thymus-independent
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ligand receptor binding
    ¸®°£µå ¼ö¿ë±â °áÇÕ
  • penicillin binding protein
    Æä´Ï½Ç¸° °áÇÕ ´Ü¹éÁú
  • plasma protein binding
    Ç÷Àå ´Ü¹é °áÇÕ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
binding energy <chemistry, radiobiology> The binding energy of a nucleus is the minimum energy required to dissociate it into its component neutrons and protons. Neutron or proton binding energies are those required to remove a neutron or proton, respectively, from a nucleus. Electron binding energy is that required to remove an electron from an atom or a molecule.
(16 Dec 1997)
binding sites The reactive parts of a macromolecule that directly participate in its specific combination with another molecule.
(12 Dec 1998)
binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
(12 Dec 1998)
calcium-binding protein <biochemistry> There are two main groups of calcium binding proteins, those that are similar to calmodulin and are called EF hand proteins and those that bind calcium and phospholipid (e.g. Lipocortin) and that have been grouped under the generic name of annexins.
Many other proteins will bind calcium, although the binding site usually has considerable homology with the calcium-binding domains of calmodulin. They can act as transport proteins, regulator proteins or activator proteins.
There is also a vitamin D-dependent variant which is a protein that plays a fundamental role in the vitamin d mediated transport of calcium in reptiles, amphibians, birds and mammals. It is found in the intestine, kidneys, egg shell gland, brain, and possibly other organs. Its molecular weight is species dependent.
(12 May 2002)
calmodulin-binding proteins Proteins which bind calmodulin. They are found in many tissues and have a variety of functions including f-actin cross-linking properties, inhibition of cyclic nucleotide phosphodiesterase and calcium and magnesium atpases.
(12 Dec 1998)
cap binding protein <molecular biology, protein> Protein (24 kD) with affinity for cap structure at 5' end of mRNA that probably assists, together with other initiation factors, in binding the mRNA to the 40S ribosomal subunit. Translation of mRNA in vitro is faster if it has a cap binding protein.
(18 Nov 1997)
galactose binding protein <protein> A bacterial periplasmic protein, most studied in E. Coli, that acts both as a sensory element in the detection of galactose as a chemotactic signal and in the uptake of the sugar.
(18 Nov 1997)
Raji cell binding test <investigation> A test for the detection of soluble IgG antigen complexes. Raji cells are a line of EBV transformed lymphocytes with surface Fc receptors. Complexes are detected by their ability to compete with a radiolabelled aggregated IgG for binding to the cells.
(18 Nov 1997)
maltose binding protein <protein> Protein of the bacterial (E. Coli) surface that links with MCP II and is involved in the chemotactic response to maltose, probably derived from a similar protein that links with a trans membrane transport system.
(18 Nov 1997)
vitamin d-binding protein An alpha-globulin found in the plasma of man and other vertebrates. It is apparently synthesised in the liver and carries vitamin d and its metabolites through the circulation and mediates the response of tissue. It is also known as group-specific component (gc). Gc subtypes are used to determine specific phenotypes and gene frequencies. These data are employed in the classification of population groups, paternity investigations, and in forensic medicine.
(12 Dec 1998)
cellular retinoic acid binding protein <protein> A cytoplasmic fatty acid binding protein that acts as an initial receptor for the putative morphogen, retinoic acid.
(18 Nov 1997)
retinol-binding protein <molecular biology> Proteins which bind with retinol.
The retinol-binding protein found in plasma has an alpha-1 mobility on electrophoresis and a molecular weight of 21,000-22,000. The protein has one binding site for retinol and is responsible for the transport of vitamin A.
The retinol- protein complex (molecular weight 80,000 to 90,000) circulates in plasma in the form of a protein-protein complex with prealbumin. The retinol-binding protein found in tissue has a molecular weight of 14,000 and carries retinol as a non-covalently-bound ligand.
(03 Jul 1999)
gonadal steroid-binding globulin A protein that transports 65% of the testosterone in plasma.
Synonym: sex steroid-binding globulin.
(05 Mar 2000)
periplasmic binding proteins Transport proteins located within the periplasmic space. Some act as receptors for bacterial chemotaxis, interacting with MCPs. Their mode of action is unclear.
(18 Nov 1997)
ribose binding protein <protein> Periplasmic binding proteins of bacteria that interact either with the ribose transport system or with the methyl accepting chemotaxis protein MCP III (trg).
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • independent school
    (¿µ) (Á¤ºÎ º¸Á¶°¡ ¾ø´Â)»ç¸³Çб³
  • independent variable
    (¼ö)µ¶¸³º¯¼ö
  • perfect binding
    antjscjf
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á